title: Comment on the PROVE1 and PROVE2 clinical trials: "I was taking a picture of Rapid Virological Response with telaprevir, but the background is unfocused!".
authors.forename: Leonardo
authors.initials: L
authors.lastname: Baiocchi
authors.forename: Ilaria
authors.initials: I
authors.lastname: Lenci
authors.forename: Marco
authors.initials: M
authors.lastname: Carbone
authors.forename: Mario
authors.initials: M
authors.lastname: Angelico
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D009842:Oligopeptides / Q000627:therapeutic use*; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D009842:Oligopeptides; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C486464:telaprevir; C100416:peginterferon alfa-2a